Karyopharm Therapeutics (KPTI) Price & Analysis

Compare

2 Followers

KPTI Stock Chart & Stats

Currently, no data available

Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProspectsInvestors' sights are on the top-line Phase 3 SENTRY trial results, expected to show promising outcomes based on previous Phase 1 results.

Market Launch PotentialThere is potential for a rapid launch in myelofibrosis, supported by high physician interest in adopting combination therapy.

Strategic FinancingStrategic financing transactions provide aggregate cash proceeds of approximately $36M, along with increased financial flexibility through interest and royalty payment deferrals.

Bears Say

Cash Runway ConcernsCurrent cash runway and recent failure to raise capital raise significant concern—downgrading to Neutral.

Revenue GuidanceFull-year guidance for Xpovio revenues was lowered.

Stock ValuationThe company's price target is lowered to $6 from $8, suggesting a less optimistic outlook on stock valuation.

Karyopharm Therapeutics News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Praxis Precision Medicines (PRAX)...

5d ago

FIG

SCO

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Trilogy Metals (TMQ) 9.29%...

12d ago

BNC

PLG

Karyopharm upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Robert Burns upgraded Karyopharm (KPTI) to Buy from Neutral with a $15 price target The...

12d ago

KPTI

Karyopharm price target lowered to $21 from $25 at Baird

Baird lowered the firm’s price target on Karyopharm (KPTI) to $21 from $25 and keeps an Outperform rating...

16d ago

KPTI

Karyopharm price target lowered to $6 from $8 at Leerink

Leerink lowered the firm’s price target on Karyopharm (KPTI) to $6 from $8 and keeps a Market Perform...

17d ago

KPTI

Morning Movers: AST SpaceMobile jumps after direct-to-cellular pact with Verizon

Stock futures have ticked modestly higher as markets look set to open with a bit of cautious optimism....

17d ago

FDX

MRX

Karyopharm announces $100M strategic financing plan

Karyopharm (KPTI) Therapeutics announced that it has entered into comprehensive financing and capital structure transactions expected to provide...

17d ago

KPTI

Karyopharm sees Q3 revenue $42-$44M, consensus $39.56M

Based on preliminary financial information, the Company expects Q3 total revenue, which includes license and royalty revenue from...

17d ago

KPTI

Karyopharm Therapeutics Completes Financing Transactions for Growth

Karyopharm Therapeutics ( ($KPTI) ) has issued an update. On October 10, 2025, Karyopharm Therapeutics Inc. completed a...

11d ago

KPTI

Karyopharm Therapeutics: Strategic Financing Extends Cash Runway Amid Cautious Hold Rating

Karyopharm Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Chang from...

17d ago

KPTI

Karyopharm Secures $100M Financing for Clinical Trials

An update from Karyopharm Therapeutics ( ($KPTI) ) is now available. On October 7, 2025, Karyopharm Therapeutics announced...

17d ago

KPTI

Selinexor Study Withdrawal: Implications for Karyopharm Therapeutics

Karyopharm Therapeutics INC (($KPTI)) announced an update on their ongoing clinical study. Study Overview: The study titled A...

22d ago

KPTI

Karyopharm Therapeutics Board Member Resigns Amid Career Shift

Karyopharm Therapeutics ( ($KPTI) ) has shared an announcement. On September 5, 2025, Mansoor Raza Mirza, M.D., a...

1M ago

KPTI

Karyopharm completes enrollment in Phase 3 Sentry trial

Karyopharm (KPTI) Therapeutics announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating...

2M ago

KPTI

KPTI FAQ

What was Karyopharm Therapeutics INC’s price range in the past 12 months?

Currently, no data Available

What is Karyopharm Therapeutics INC’s market cap?

Currently, no data Available

When is Karyopharm Therapeutics INC’s upcoming earnings report date?

Karyopharm Therapeutics INC’s upcoming earnings report date is Oct 30, 2025 which is in 5 days.

How were Karyopharm Therapeutics INC’s earnings last quarter?

Karyopharm Therapeutics INC released its earnings results on Aug 11, 2025. The company reported -$3.436 earnings per share for the quarter, missing the consensus estimate of -$3.247 by -$0.189.

Is Karyopharm Therapeutics INC overvalued?

According to Wall Street analysts Karyopharm Therapeutics INC’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Karyopharm Therapeutics INC pay dividends?

Karyopharm Therapeutics INC does not currently pay dividends.

What is Karyopharm Therapeutics INC’s EPS estimate?

Karyopharm Therapeutics INC’s EPS estimate is -2.76.

How many shares outstanding does Karyopharm Therapeutics INC have?

Currently, no data Available

What happened to Karyopharm Therapeutics INC’s price movement after its last earnings report?

Karyopharm Therapeutics INC reported an EPS of -$3.436 in its last earnings report, missing expectations of -$3.247. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Karyopharm Therapeutics INC?

Currently, no hedge funds are holding shares in CH:KPTI

Company Description

Karyopharm Therapeutics INC

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics (KPTI) Earnings & Revenues

Historic Earnings Reports

KPTI Company Deck

KPTI Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented a mix of positive progress in clinical trials and commercial performance, especially with a steady increase in revenue from XPOVIO and global expansion efforts. However, significant financial challenges due to a net loss, decline in total revenue, and approaching debt maturity are concerning. The company is actively working on strategic alternatives to enhance liquidity.View all CH:KPTI earnings summaries

Similar Stocks

ATNM

Actinium Pharmaceuticals

―

BTAI

Bioxcel Therapeutics

―

LTRN

Lantern Pharma

―

IPSC

Century Therapeutics